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Cancer chemoprevention can be defined as prevention of cancer by the administration of one or
more chemical entities, either as individual drugs or as naturally occurring constituents of the diet.
Based largely on the time period that chemopreventive agents exhibit activity in animal models of
carcinogenesis, they can be classified as inhibitors of carcinogen formation, blocking agents, and
suppressing agents. The majority of compounds that inhibit the formation of carcinogens prevent
the formation of nitrosamines from secondary amines and nitrite in an acidic environment.
Blocking agents are inhibitors of tumor initiation, while suppressing agents are inhibitors of tumor
promotion/progression. Many well-characterized chemopreventive agents act at one or more
steps in both tumor initiation and promotion/progression. The objective of this paper is to provide
a general discussion of the mechanisms through which chemopreventive agents inhibit
carcinogenesis. Examples of agents that act through these mechanisms are given; however, a
complete listing of effective chemopreventive agents is not possible within the context of this
paper. At the conclusion is a brief discussion of future prospects in cancer chemoprevention and
obstacles to overcome. Environ Health Perspect 1 05(Suppl 4):945-954 (1997)
Key words: cancer, chemoprevention, mechanisms, anti-initiation, antipromotion,
antiprogression
Introduction
Cancer chemoprevention can be defined as
the prevention, inhibition, or reversal of
carcinogenesis by administration of one or
more chemical entities, either as individual
drugs or as naturally occurring constituents
ofthe diet. Knowledge ofchemoprevention
science and its application in clinical studies
has been growing rapidly over the past
decade, as has been documented in reviews
ofthe field prepared by us and by others
(1-8). This paper serves as an update and
briefcommentary on the status and various
aspects ofchemoprevention.
Epidemiological studies indicate that
approximately 80% of human cancer is
caused by exposure to chemical carcinogens
in tobacco smoke, in the diet, and in the
workplace (9,10). Given these observations,
at least three approaches to the preven-
tion of cancer can be envisioned. First,
reduce human exposure to environmental
carcinogens through careful monitoring of
the workplace and through educational
approaches to encourage changes in lifestyle.
Second, identify individuals at high risk for
cancer development through predisposing
genetic or biochemical factors, followed by
appropriate clinical follow-up. Third,
provide chemoprevention by dietary or syn-
thetic means. For several reasons, chemopre-
vention has received growing consideration
as a means of cancer control. In certain
organ sites such as the lung, pancreas, stom-
ach, ovary, and esophagus, the development
ofcancer leads to exceptionally low 5-year
survival rates. Clearly, the considerable
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advances that have occurred in earlier detec-
tion and treatment ofcancer have done lit-
tle to improve the prognosis for patients
diagnosed with cancer at certain organ sites.
Primary cancer prevention requires removal
of exposure to etiologic agents. Although
this is an important approach to cancer pre-
vention, it is not always effective, as evi-
denced by the marginal success oftobacco
cessation programs. Moreover, numerous
populations at high risk for certain types
ofcancer may already have received consid-
erable exposure to etiologic agents, and
many human cancers cannot be ascribed to
specific agents. Thus, preventive strategies
that do not require prior knowledge of
specific etiological factors have great
appeal. Additionally, the success obtained
in chemoprevention of cancer in animal
models provides a strong mandate for this
approach to cancer prevention in humans.
Target Populations
The projected target populations for cancer
chemoprevention consist of high-risk
groups, such as the following: individuals
with high exposure to carcinogens (e.g.,
tobacco smokers and populations that con-
sume foodstuffs contaminated with fungal
toxins and nitrosamines); those who are
known to be genetically predisposed to the
development of cancer (e.g., patients with
familial colonic polyposis); individuals
with premalignant lesions (e.g., oral leuko-
plakia, Barrett's esophagus, dysplastic nevi,
etc.); individuals with occupational expo-
sure to known carcinogens; and survivors
of primary cancers with a high degree of
recurrence or a marked tendency toward
formation ofsecond primary tumors. Some
controversy remains as to whether or not
chemopreventative strategies (other than
certain dietary measures) will or should be
used in the general population.
Classes ofChemopreventive
Agents
Absolute classification ofchemopreventive
agents is difficult because the precise mech-
anisms of action are not known for many
compounds. In addition, many chemopre-
ventive agents act through more than one
mechanism, making it difficult, if not
impossible, to establish the most effective
mode of action. The classification scheme
developed by Wattenberg (11) is based
essentially on the time period during which
agents appear to exhibit activity in animal
models of carcinogenesis. On this basis,
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Table 1. Inhibitors ofcarcinogen formation.
Chemical class Inhibitor
Reductive acids Ascorbic acid
Phenols Caffeic acid, ferulic acid,
gallic acid
Sulfhydryl compounds N-Acetylcysteine
Amino acids Proline, thioproline
chemopreventive agents are classified as
inhibitors ofcarcinogen formation, blocking
agents, and suppressing agents. Blocking
agents are inhibitors of tumor initiation,
while suppressing agents are inhibitors of
tumor promotion/progression. Examples of
the three major classes ofchemopreventive
agents are given below.
Inhibitors of
Carcinogen Formation
Chemopreventive agents that inhibit the
formation of carcinogens act predomi-
nantly to prevent the formation of nitro-
samines from secondary amines and nitrite
in an acidic environment. A list of these
agents is given in Table 1. When present in
appreciable amounts, ascorbic acid
decreases nitrosamine production from sec-
ondary amines and nitrite in the stomach
(12), thus leading to a diminished lung
tumor response in mice (13). Other com-
pounds that inhibit nitrosamine formation
include phenols such as ferulic, gallic, and
caffeic acids (14), as well as several
sulfhydryl compounds (15). Proline and
thioproline scavenge nitrite by reacting
with it to form nonmutagenic nitrosamines
(16). Compounds of this class may have
utility when incorporated into the diet of
populations with suspected high rates of
endogenous formation ofnitrosamines.
BlockingAgents
There are several means of chemical
intervention at the initiation stage of
carcinogenesis. It is well known that most
environmental procarcinogens must first be
metabolically activated to electrophilic forms
that damage DNA while to some extent
avoiding pathways ofmetabolic detoxifica-
tion. The electrophilic species reacts with
DNA, forming adducts that result in base
mispairing and mutation. On this basis,
most blocking agents can be assigned to one
or more offive major categories (Table 2):
inhibitors ofcytochrome P450 enzymes;
inducers ofcytochrome P450 enzymes;
inducers ofphase II enzymes such as glu-
tathione S-transferase (GST), urine diphos-
phate (UDP)-glucuronyltransferase, and
Table 2. Categories of blocking agents.a
Mechanism Examples
Inhibition ofcytochrome P450 Dithiocarbamates, ellagic acid, diallyl sulfide, isothiocyanates
Induction of cytochrome P450 Indole-3-carbinol, j-naphthoflavone
Induction of phase 11 enzymes
Glutathione S-transferase Allyl sulfides, dithiolethiones, isothiocyanates
UDP-glucuronyltransferase Polyphenols
Glutathione peroxidase Selenium
Scavenge electrophiles Ellagic acid, N-acetylcysteine
Scavenge free radicals Sodium thiosulfate, polyphenols, vitamin E
Increase overall levels of DNA repair Vanillin
Increase poly(ADP-ribosyl)transferase N-Acetylcysteine
Suppress error-prone DNA repair Protease inhibitors
aAfter Morse and Stoner(1) and Kelloff etal. (70).
glutathione peroxidase; scavengers of
electrophiles and free radicals; and inducers
ofDNArepair.
Inhibitors of Cytochrome P450
Enzymes. One of the first cytochrome
P450 inhibitors shown to exhibit chemo-
preventive activity was disulfiram, which
inhibits the activation ofdimethylhydrazine
(17) and colon cancer induced by this
compound. The isothiocyanates are strong
P450 inhibitors and among the most
potent chemopreventive agents known
(18-28). For example, dietary phenethyl
isothiocyanate, at a concentration of
3mmol/kg diet, can inhibit 4-(methylni-
trosamino)- 1-(3-pyridyl)-1-butanone
(NNK)-induced lung tumors in F344 rats
by approximately 50% (20). This concen-
tration completely inhibits N-nitro-
somethylbenzylamine (NMBA)-induced
esophageal tumors in F344 rats (24).
6-Phenylhexyl isothiocyanate inhibits
NNK-induced lung tumorigenicity by
> 80% in strain A mice when administered
at a dose of50-fold lower than NNK (23).
Unfortunately, 6-phenylhexyl isothio-
cyanate appears to promote azoxymethane-
induced colon tumors and NMBA-induced
esophageal tumors in F344 rats (28). These
results illustrate the importance of utiliz-
ing more than one animal model system in
evaluating the efficacy ofchemopreventive
agents. Diallyl sulfide, a naturally occur-
ring constituent ofAllium vegetables,
inhibits carcinogen activation and tumori-
genesis in several animal models (29-32).
Ellagic acid inhibits benzo[a]pyrene
metabolism in vitro (33), NMBA metabo-
lism in vivo and in vitro (34,35), and
inhibits NMBA-induced esophageal
tumors (36,37).
Inducers of Cytoehrome P450
Enzymes. Another mechanism ofaction of
blocking agents is through induction of
cytochrome P450. Inducers ofcytochrome
P450 act either by increasing the metabolic
activation of carcinogens in nontarget
tissues or by enhancing oxidative detoxifi-
cation at any tissue site. Indole-3-carbinol
(I3C) is a potent inducer ofP450 enzymes
and has chemopreventive activity in several
animal models (38-44). Compounds that
induce P450 enzymes, however, may pro-
mote cancer at other organ sites through
enhanced carcinogen activation at these
sites; this may, at least in part, account for
the known cocarcinogenic or promotional
activity of13C (45-47).
InducersPhaseIIEnzymes. Inducers of
phase II detoxifying enzymes are preferred
to cytochrome P450 inducers as chemopre-
ventive agents because they are less likely to
produce cancers themselves. Sulforaphane,
an isothiocyanate found in broccoli (48), is
a potent inducer ofGST and inhibits chem-
icallyinduced mammary cancer in rats (49).
Another potent inducer ofGST is the dithi-
olethione, oltipraz, which inhibits carcino-
gen-induced tumorigenesis in a number of
animal models (50-56). Butylated hydrox-
yanisole (BHA) stimulates UDP-glu-
curonyltransferase activity, and this appears
to be the mechanism by which BHA
inhibits benzo[a]pyrene tumorigenesis in
the mouse forestomach (57,58).
Scavengers ofElectrophiles andFree
Radicas. Scavenging or trapping agents are
compounds that physically react with the
activated (electrophilic) forms ofcarcino-
gens and oxygen free radicals. Ellagic acid
reacts directly with the diolepoxide of
benzo[a]pyrene (BPDE) to form both cis-
and trans- adducts (59); such activity may
account for its inhibition ofBPDE-induced
mutagenicity and carcinogenicity (60,61).
The sulfhydryl moiety ofN-acetylcysteine
(NAC) can accept electrophilic species,
which may account for its antimutagenic
and anticarcinogenic effects (62-64).
Oxygen free radicals are produced by
the metabolism ofseveral carcinogens and
by inflammatory cells (65). Numerous
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chemopreventive agents exhibit antioxidant
activity through their ability to scavenge
oxygen radicals, including, for example,
singlet oxygen, peroxy radicals, superoxide
anion, and hydroxyl radicals. For example,
NAC and other chemopreventive thiols are
known to react with hydroxyl radicals
(66). The reaction of,B-carotene with sin-
glet oxygen and its participation in other
free radical-trapping reactions is well docu-
mented (67,68). Phenolic antioxidants are
known to scavenge peroxy radicals; in par-
ticular, vitamin E is known to scavenge
peroxy radicals, singlet oxygen, and super-
oxide radicals (69). Other phenols such as
ellagic acid, curcumin, caffeic acid phenyl
ester, and the tea polyphenols are particu-
larly active oxygen radical scavengers, due
likely to the presence ofhydroxyl groups
on adjacent carbons in these compounds.
Nonphenolic antioxidants also scavenge
oxygen free radicals. For example, glu-
tathione reacts with alkyl-peroxy radicals
(69). A disadvantage ofscavenging agents
is that they must be present at sufficient
concentrations in target tissues at all times
during which carcinogens or free radicals
are present.
Inducers ofDNA Repair. There are
three possible chemopreventive mechanisms
that involve DNA repair (70,71). The first
is an increase in the overall level of DNA
repair. An example ofa naturally occurring
chemical that increases the level of DNA
repair is vanillin, which inhibits mammalian
cell mutagenicity (72). The mechanisms
through which vanillin promotes DNA
repair have not been determined. Second,
the enzyme poly(ADP-ribosyl)transferase
(ADPRT) is involved in modulation of
DNA damage (73,74), and the level ofthis
enzyme is reduced by chemical carcinogens
(75). N-Acetylcysteine prevents the decrease
in ADPRT caused by the carcinogen
2-acetylaminofluorene (AAF) (75). The
third mechanism is suppression of error-
prone DNA repair. Protease inhibitors
depress error-prone repair in bacteria (76),
and it has been suggested that they could
prevent carcinogenesis by inhibiting an
error-prone repair system activated by pro-
teases that, in turn, are induced by tumor
promoters (77).
Many would argue that the use of
blocking agents is not a feasible approach to
chemoprevention in humans, since all
members ofhigh risk groups have presum-
ably received some exposure to initiating
agents. The work ofVogelstein et al. (78)
and Fearon andVogelstein (79) on colorec-
tal cancer, however, indicates that human
Table 3. Categories of suppressing agents.a
Mechanism Examples
Inhibit polyamine metabolism DFMO, polyphenols, substituted putrescines
Induce terminal cell differentiation Calcium, retinoids, vitamin D3
Modulate signal transduction Glycyrrhetinic acid, NSAIDs, polyphenols, retinoids
Modulate hormonal/growth factoractivity NSAIDs, retinoids, tamoxifen
Inhibit oncogene activity Genistein, NSAIDs, monoterpenes
Promote intracellular communication Carotenoids, polyphenols, retinoids
Restore immune response NSAIDs, selenium, vitamin E
Induce apoptosis Butyric acid, genistein, selenium, sulindac sulfone,
retinoids
Correct DNA methylation imbalances Folic acid, choline, methionine
Inhibit basement membrane degradation Protease inhibitors
Inhibit arachidonic acid metabolism Glycyrrhetinic acid, N-acetylcysteine, NSAIDs,
polyphenols
"After Kelloff etal. (70).
cancer is not adequately represented by the
traditional initiation/promotion model,
but more likely involves an accumulation
ofmutational events in key genes such as
the oncogenes and tumor suppressor genes.
Ifthat is so, then administration ofblock-
ing agents should prove of some value,
since many individuals at high risk (e.g.,
smokers and the occupationally exposed)
are continually exposed to genotoxic car-
cinogens. Moreover, it could also be
important to inhibit further mutational
events in individuals who have a reduced
exposure to carcinogens but remain at
higher risk for cancer development (e.g.,
former tobacco smokers). Individuals who
are genetically predisposed to cancer must
avoid further mutational events that could
trigger the carcinogenesis process; such
individuals are excellent candidates for
prophylactic treatment with blocking
agents. Also, the administration of
inhibitors ofpromotion/progression will be
helpful in combating the effects of expo-
sure to a wide range of carcinogens, no
matter what model human carcinogenesis
follows. Co-administration ofblocking and
suppressing agents is a promising strategy
for optimizing efficacy.
SuppressingAgents
Classification ofsuppressing agents is more
difficult because the critical events and
their exact sequence in the processes of
tumor promotion and progression are not
well understood. However, as described by
Morse and Stoner (1), De Flora and Ramel
(80), and Kelloff et al. (70,71), many cur-
rent suppressing agents can be classified as
compounds that inhibit polyamine metab-
olism; induce terminal cell differentiation;
modulate signal transduction; modulate
hormonal/growth factor activity; inhibit
oncogene activity; promote intercellular
communication; restore immune response;
induce apoptosis; correct DNA methylation
imbalances; inhibit basement membrane
degradation; and inhibit arachidonic acid
metabolism (Table 3).
Inhibiters ofPolyamine Metabolism.
The polyamine content of cells is corre-
lated to their proliferative, and often their
neoplastic, capabilities (81). A key enzyme
in the polyamine biosynthetic pathway,
ornithine decarboxylase (ODC), catalyzes
the conversion of ornithine to putrescine
(82). The levels of ODC and polyamines
are frequently elevated in tumor tissues rel-
ative to their normal counterparts. In addi-
tion, phorbol ester tumor promoters such
as 12-tetradecanoylphorbol-13-acetate
(TPA) cause increased ODC activity and
accumulation ofpolyamines in affected tis-
sues (83). Inhibitors ofpolyamine metabo-
lism include the suicide inhibitor ofODC,
a-difluoromethylornithine (DFMO) (84).
DFMO inhibits tumorigenesis induced by
a number ofdifferent carcinogens (85-92).
Other chemopreventive agents such as the
tea polyphenols, ellagic acid, and cur-
cumin, inhibit ODC activity; presumably,
this is one mechanism through which these
compounds inhibit TPA-induced tumor
promotion in mouse skin. Due to the rapid
turnover ofODC (81), constant levels ofa
given ODC inhibitor must be maintained
at the target organ to achieve the desired
antiproliferative activity.
Inducers of Terminal Cell
Differentiation. Terminal differentiation
is one ofthe steps in the normal, regulated
cell proliferation in epithelial tissues.
Cancer cells often have lost the ability to
differentiate (93). Abundant evidence indi-
cates that restoring the ability of abnor-
mally proliferating cells to differentiate
suppresses carcinogenesis. Vitamin A and
the retinoids are the most extensively
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studied differentiation agents. It has been
known for many years that vitamin A defi-
ciency causes squamous metaplasia and
keratinization; both are signs of uncon-
trolled proliferation (94). Studies in ham-
ster trachea (95-97) show that treatment
of squamous keratinizing epithelium with
vitamin A restores normal mucociliary dif-
ferentiation. Retinoids appear to control
differentiation via intracellular binding
proteins and nuclear receptors (98-100).
Calcium and vitamin D3 are differenti-
ating agents that also inhibit carcinogenesis
in animal models. Calcium induces differen-
tiation in a number ofepithelial tissues,
including mouse skin (101), rat esophagus
(102), human colon (103), and human
mammary gland (104,105). Vitamin D3
induces differentiation in avariety ofhuman
and animal tissues (106-109). The effects
ofcalcium and vitamin D3 may be mediated
by the same signal transduction pathway,
involving the vitamin D3 nuclear receptor
with calcium as the messenger (93).
Modulators ofSignal Transduction.
The components of signal transduction
pathways provide multiple sites for chemo-
preventive activity by restoring normal cel-
lular growth control. In fact, many ofthe
antipromotion/antiprogression activities
important to chemoprevention impact one
or more components of signal transduc-
tion pathways. For example, one of the
steps in signal transduction involves acti-
vation ofprotein kinase C (PKC) by diacyl
glycerol. Several chemopreventive agents,
such as the flavonoids and glycyrrhetinic
acid, have inhibited PKC activity leading
to suppression ofcarcinogenesis (70,71).
Further, invocation ofthe signal trans-
duction pathways provides a mechanistic
rationale for the multiple chemopreventive
effects ofsome agents. For example, agents
such as the retinoids and PKC inhibitors,
which affect activities at the cell mem-
brane, cytoplasmic, and nuclear membrane
levels, can also affect other connected
events such as growth factor expression and
polyamine metabolism (70,71).
Modulators ofHormonal/Growth
FactorActivity. Chemopreventive agents
may inhibit neoplastic cell proliferation by
directly regulating the induction and
activity ofspecific hormones and growth
factors that initiate steps in signal transduc-
tion. This regulation may occur at mem-
brane level receptors (for growth factors
and peptide hormones) or through cyto-
plasmic and nuclear receptors (for the
steroid family of receptors). For example,
transforming growth factor-5 (TGF-3) has
antiproliferative activity in both normal
and neoplastic cells in vitro and in vivo
(110-113). Neoplastic cells such as A549
human lung carcinoma cells produce TGF-
3, but in a latent form that cannot bind to
its membrane receptor; these cells are
responsive to the antiproliferative effects of
activatedTGF-0 (110). Antiestrogens such
as tamoxifen bind to nuclear estrogen
receptors, preventing the binding and
activity ofestrogens (114). There is also
evidence ofcrossregulation among mem-
brane and nuclear receptors. For example,
insulinlike growth factor I (IGF-I) stimu-
lates cell replication in various tumors
(115,116). Human breast cancer cells have
membrane receptors for and excrete IGF-I
(115). Tamoxifen lowers blood concentra-
tions of IGF-I in breast cancer patients,
which may in part be responsible for its
antitumor activity (115).
Inhibitors ofOncogeneActivity. Most
studies on the ability ofchemopreventives
to inhibit oncogene activity have con-
cerned the ras gene. To be activated, the
ras gene protein must first be farnesylated.
ras Oncogenes are involved in mammary
gland carcinogenesis induced by methylni-
trosourea (MNU) and, to a lesser extent,
by 7,12-dimethylbenz[a]anthracene
(DMBA). Gould and colleagues (117,118)
showed that D-limonene, found in citrus
oils, inhibits the progression ofmammary
tumors induced in rats by either MNU or
DMBA. They also showed that D-limonene
inhibits farnesylation ofsmall G proteins;
these data suggest that D-limonene pre-
vents oncogene activation by inhibiting
posttranslational farnesylation of the ras
p21 protein (119).
Investigations in vitroindicate inhibition
ofoncogene expression as a mechanism for
inhibitory activity of protease inhibitors
and retinoids. For example, the protease
inhibitors 6-aminocaproic acid, leupeptin,
and antipain inhibit transformation of
NIH-3T3 cells transfected with activated
H-ras oncogenes (120). Retinoic acid also
inhibits H-ras-induced transformation in
NIH-3T3 cells (120).
Promoters of Intercellular
Communication. Communication between
cells is mediated through gap junctions.
Gap junctions are pores or channels in the
cell membrane, which join channels ofadja-
cent cells; when open, these channels allow
passage ofmolecules up to approximately
1000 d in size (121,122). Lowenstein (123)
and Mehta et al. (124,125) have proposed
that gap junctions allow growth regulatory
signals to move between cells. Numerous
studies have shown that inhibition of
gap-junctional communication between
cells occurs during carcinogenesis. Several
carotenoids such as 5-carotene and canthax-
anthine, and retinoids such as [E]-
4(2,5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-
2-naphthalenyl)-l-propenyl)-benzoic acid
and vitaminA, have been shown to enhance
gap junctional communication in chemi-
cally treated C3H1OT1/2 cells in vitro
(126). This enhancement ofcommunica-
tion correlated with inhibition oftransfor-
mation ofthese cells and was mediated by
upregulation ofconnexin proteins involved
in gap-junction formation (126).
Restorers of Immune Response.
Chemopreventive agents influence the
immune response through a number of
mechanisms. For example, retinoic acid
increases cell mediated and natural killer
(NK) cell cytotoxicity; retinoids also cause
leukemic promyelocytes to differentiate to
mature granulocytes comparable to mature
neutrophils (127). These effects might be
partially responsible for the activity of
retinoids against established tumors (128).
Both thymocytes and NK cells from sele-
nium-deficient mice have a decreased abil-
ity to destroy tumor cells in vitro (129).
Supplementation with 0.5 or 2 ppm sele-
nium enhances the ability of rat NK cells
to kill tumor cells.
Vitamin E also produces stimulatory
effects on the immune system. Pharma-
cological doses ofvitamin E fed with nor-
mal animal diets increases humoral
antibody production, especially IgG (130).
Vitamin E also stimulates cell mediated
immunity (131) and prevents the carcino-
gen-induced decrease in the density of
macrophage-equivalent cells (Langerhans
cells) in the oral cavity of DMBA-treated
hamsters (132).
Inducers ofApoptosis. Apoptosis
(programmed cell death) is a well-regu-
lated function of the normal cell cycle
(133,134). Tumor suppressors, such as
wild-type p53 (135,136), and growth fac-
tors, such as TGF-f (137), have been
implicated as inducers of apoptosis.
Apoptosis is inhibited by tumor promoters
such as TPA (136,137) and other
chemicals that stimulate cell proliferation,
such as hormones (134,138,139). These
results suggest that induction ofapoptosis
may inhibit tumor formation. Although
there have not been a large number of
reports as yet, certain chemopreventive
agents have been demonstrated to induce
cellular apoptosis. For example, tamoxifen
induces programmed cell death in human
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mammary cancer MCF-7 cells (134).
Apoptosis in colonic tissues is induced by
sulindac sulfone, a metabolite of the
nonsteroidal anti-inflammatory drug
(NSAID) sulindac (140). This may be a
major mechanism by which sulindac
inhibits development of polyps in the
human colon (141,142).
Correctors of DNA Methylation
Imbalances. A number of studies have
shown that methyl-deficient diets increase
cell turnover and promote the devel-
opment ofcarcinogen-induced liver tumors
in rats and mice (143-146). In contrast,
methyl-rich (fortified with choline and
methionine) diets prevent or reduce these
effects in the liver (147-149). Changes in
the expression levels of protooncogenes
and decreased expression ofgrowth factors
and growth factor receptors occur in
animals on methyl-deficient diets
(143,150,151). The increased protoonco-
gene expression correlates with hypo-
methylation of the protooncogenes
(143,150). Collectively, these data suggest
that hypomethylation of DNA results in
changes in the expression ofgenes involved
in cellular growth control (143,148).
Certain compounds that serve as methyl
group donors inhibit tumorigenesis.
Methionine, which is involved with
choline, folic acid, and vitamin B12 in reg-
ulating intracellular methyl metabolism,
inhibits chemically induced mammary
cancer in rats; choline inhibits chemically
induced liver tumors in rats (143,145).
Inhibitors ofBasement Membrane
Degradation. Cancer cells produce various
enzymes that digest the basement mem-
brane and allow the cells to invade through
normal tissues. These enzymes include the
proteases collagenase, hyaluronidase, cathep-
sin B, elastase, and plasminogen activators
(120,152). Protease inhibitors inhibit the
activities oftype IV collagenase and throm-
bin, which are among the proteases that par-
ticipate in the destruction ofthe basement
membrane during tumor invasion (120).
Thus protease inhibitors may exert their
protective effects in part by inhibiting the
degradation ofthe basement membrane.
Inhibitors of Arachidonic Acid
Metabolism. Among the multiple events
that occur during experimentally induced
tumor promotion is an increased metabo-
lism ofarachidonic acid, which contributes
to an overall inflammatory response (81).
The cyclooxygenase pathway converts
arachidonic acid to prostaglandins, prostacy-
clins, and thromboxanes, while lipoxygenase
conveirts arachidonic acid to leukotrienes
and hydroxyeicosatetraenoic acids (153).
Activated oxygen species and alkylperoxy
species are formed throughout this process.
Relative to these events, the cyclooxygenase
inhibitors such as NSAIDs (e.g., aspirin,
indomethacin, ibuprofen, piroxicam) and
certain antioxidants (e.g., flavonoids) are
effective inhibitors of carcinogenesis
(153-157). Compounds that inhibit
lipoxygenase, such as vitamin E, inhibit
tumor promotion in mouse skin. Likewise,
lipoxygenase inhibitors that are stable one-
electron donors-which competitively
inhibit the production ofunstable free radi-
cals and electrophiles by prostaglandin H
synthase (e.g., curcumin, the tea polyphe-
nols, the flavonoids)-also inhibit tumor
promotion in mouse skin (158-160). Since
the products ofarachidonic acid metabolism
could contribute to both the initiation and
promotion/progression stages ofcarcinogen-
esis, inhibitors ofarachidonic acid metabo-
lism may act as either blocking agents or
suppressing agents.
Kelloff et al. (70,71) have discussed
other mechanisms by which suppressing
agents might inhibit molecular and cellular
events associated with the promotion/pro-
gression stages of carcinogenesis; e.g.,
restoration of tumor suppressor function,
inhibition of angiogenesis, and activation
ofantimetastasis genes. Although these are
logical targets for chemoprevention, at
present there is little evidence to suggest
that known chemopreventive agents act
through these mechanisms.
Future Prospects and
Obstacles to Overcome
The large body ofinformation on carcino-
genesis and chemopreventive mechanisms
that has been summarized in this report
has been developed, for the most part, in
the past 15 to 20 years. This information
provides a strong base for future mechanis-
tic studies in chemoprevention as well as
for the design and development ofclinical
investigations. Indeed, a number ofphase
I, II, and III clinical trials ofchemopreven-
tive agents are underway and some success
has already been achieved. For example,
Hong et al. (161) showed that isotretinoin
inhibited the development ofsecond pri-
mary tumors in patients treated for pri-
mary cancers of the head and neck.
Garewal et al. (162) showed regression of
oral leukoplakia in individuals treated with
P-carotene. Several studies have demon-
strated the ability ofthe nonsteroidal anti-
inflammatory agent, sulindac, to cause
regression of colonic polyps (141,142).
However, the results ofsome clinical trials
have not been as promising, and future
success in clinical trials is needed to further
establish chemoprevention as a plausible
approach to the prevention of human
cancer. In this respect, the progressive
increase in research activity on the basic
mechanisms ofaction ofchemopreventive
agents during the past few years is gratify-
ing and is likely to result in an even
stronger database from which to design
clinical trials in the future.
In a previous report (1), we discussed in
considerable detail some ofthe obstacles to
be overcome in the field ofcancer chemo-
prevention. Among these is the relative lack
of participation of the pharmaceutical
industry. A major concern ofthe pharma-
ceutical industry is the length oftime and
the cost to conduct phase III clinical trials of
efficacyofchemopreventive agents. To some
degree, this problem could be overcome by
U.S. Food and DrugAdministration (FDA)
approval ofthe use ofchemopreventives in
populations at high risk to cancer based on
the successful modulation ofsurrogate end
point biomarkers in phase II trials (3,4,6,7).
To this end, the National Cancer Institute
(NCI) and the FDA have produced consen-
sus guidance on the development of
chemopreventive agents that emphasizes
the evaluation and validation of such
surrogate end points (163).
Another obstacle is that of subject
compliance and recruitment. Subject com-
pliance with the chronic dosing regimens
ofchemopreventative clinical trials could
be a considerable problem. Also, early
withdrawal ofsubjects from multiyear pro-
tocols conducted at a single site can be a
frequent occurrence in a highly mobile
society. Finally, recruitment ofa sufficient
number ofsubjects for large-scale clinical
trials can be difficult ifthe subjects are not
highly motivated.
Another obstacle to chemoprevention is
funding for basic research and for clinical
trials. As we described previously, the NCI
Chemoprevention Branch has a comprehen-
sive, science-based chemopreventive agent
drug development program ranging from
drug discovery through phase III clinical
trials (2-7,163). Similarly, other compo-
nents of the NCI Cancer Prevention
Research Program fund large chemopreven-
tion clinical trials. However, such efforts
represent only a fraction ofthose required to
make rapid progress in chemoprevention. In
1990, in the United States alone, total costs
associatedwith neoplasticdiseases have been
estimated at > $100 billion (164). The
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costs oftreating cancer increase annually at
a rate greater than inflation. A reduction in
cancer incidence ofonly 10% would result
in substantial savings. The impressive
advances made with chemopreventive
agents in experimental models and the
encouraging results ofsome ofthe clinical
trials clearly warrant increased research in
chemoprevention. Those engaged in
research in chemoprevention must become
more involved in funding decisions that
affect the field.
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